191 related articles for article (PubMed ID: 29123258)
1. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.
Hugdahl E; Kalvenes MB; Mannelqvist M; Ladstein RG; Akslen LA
Br J Cancer; 2018 Jan; 118(1):98-105. PubMed ID: 29123258
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
3. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
4. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
Ofner R; Ritter C; Heidenreich B; Kumar R; Ugurel S; Schrama D; Becker JC
J Cancer Res Clin Oncol; 2017 Apr; 143(4):613-617. PubMed ID: 27990595
[TBL] [Abstract][Full Text] [Related]
5.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
6. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
10. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations in familial and sporadic melanoma.
Horn S; Figl A; Rachakonda PS; Fischer C; Sucker A; Gast A; Kadel S; Moll I; Nagore E; Hemminki K; Schadendorf D; Kumar R
Science; 2013 Feb; 339(6122):959-61. PubMed ID: 23348503
[TBL] [Abstract][Full Text] [Related]
12. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis.
Motaparthi K; Kim J; Andea AA; Missall TA; Novoa RA; Vidal CI; Fung MA; Emanuel PO
J Cutan Pathol; 2020 Aug; 47(8):710-719. PubMed ID: 32202662
[TBL] [Abstract][Full Text] [Related]
13. Classifying Melanoma by TERT Promoter Mutational Status.
Shaughnessy M; Njauw CN; Artomov M; Tsao H
J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705
[TBL] [Abstract][Full Text] [Related]
14. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
[TBL] [Abstract][Full Text] [Related]
15. High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma.
Ekedahl H; Lauss M; Olsson H; Griewank KG; Schadendorf D; Ingvar C; Jönsson G
Pigment Cell Melanoma Res; 2016 Sep; 29(5):598-600. PubMed ID: 27301352
[No Abstract] [Full Text] [Related]
16. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
17. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B; Nagore E; Rachakonda PS; Garcia-Casado Z; Requena C; Traves V; Becker J; Soufir N; Hemminki K; Kumar R
Nat Commun; 2014 Feb; 5():3401. PubMed ID: 24569790
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.
Lin SY; Liao SL; Hong JB; Chu CY; Sheen YS; Jhuang JY; Tsai JH; Liau JY
Br J Ophthalmol; 2016 Feb; 100(2):274-7. PubMed ID: 26472403
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma.
Cho WC; Li W; Gu J; Wang WL; Ning J; Sfamenos S; Gill P; Nagarajan P; Curry JL; Lazar AJ; Prieto VG; Torres-Cabala CA; Aung PP
J Cutan Pathol; 2023 Sep; 50(9):845-851. PubMed ID: 37400233
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.
Griewank KG; Murali R; Schilling B; Schimming T; Möller I; Moll I; Schwamborn M; Sucker A; Zimmer L; Schadendorf D; Hillen U
PLoS One; 2013; 8(11):e80354. PubMed ID: 24260374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
